Our proprietary QTORIN™ technology has broad potential to deliver targeted therapies for a spectrum of genetic diseases.
The Power of QTORIN™
Palvella’s proprietary QTORIN™ technology was developed over several years of research to overcome inherent challenges with topical delivery of mTOR inhibitors such as rapamycin – including chemical stability, skin penetration, and skin distribution. QTORIN™ is an anhydrous gel comprising excipients precisely selected in an optimized ratio to achieve drug stability at room temperature and enable cutaneous distribution into the keratinocytes in the basal layer of the epidermis and to the reticular dermis, where the pathology manifests in many dermatologic conditions. Two of Palvella’s programs, PTX-022 and PTX-367, leverage QTORIN™ to deliver the active agent directly to the root genetic cause of each disease. QTORIN™ offers potential applicability to a wide range of diseases and therapeutic agents, including single agents and combination therapies.
QTORIN™ enables excellent stability to mTOR inhibitors, which are highly susceptible to degradation, particularly in aqueous environments. Our QTORIN™ Rapamycin is minimally degraded at room temperature in our pump dispenser and in the skin for extended periods.
High Concentration Capacity
QTORIN™ attains rapamycin concentrations up to 3.9% and beyond – significantly greater than was pharmaceutically achievable previously. This high-strength formulation is designed to provide maximum local therapeutic effect with minimal systemic side effects.
Rapid Dermal Penetration
Due to their high molecular weight and chemical composition, mTOR inhibitors have poor skin absorption, historically limiting their therapeutic use. There are no FDA-approved topical mTOR inhibitors. Our QTORIN™ rapamycin formulation yields effective epidermal and dermal distribution.